Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 1831169 + Ezabenlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 1831169 | BI1831169|BI-1831169 | BI 1831169 is a vesicular stomatitis virus (VSV)-derived oncolytic chimeric virus containing a modified glycoprotein, which may lead to reduced neurotoxicity, increased tumor lysis, and immune cell-mediated tumor cell killing (PMID: 35699077, PMID: 24812275). | ||
Ezabenlimab | BI754091|BI-754091|BI 754091 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05155332 | Phase I | BI 1831169 + Ezabenlimab BI 1831169 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors). | Recruiting | USA | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |